Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antago-tRF-21
- Development stage
- Preclinical
- Lead developer
- Qilu Hospital of Shandong University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
antago-tRF-21 is an antagomir (antisense oligonucleotide) designed to target and inhibit tRNA-derived fragment tRF-21 [P0995]. In renal cell carcinoma (RCC), tRF-21 is highly expressed and contributes to an immunosuppressive tumor microenvironment (TME) by binding to DAZAP1, preventing its deacetylation by SIRT2, and promoting its nuclear translocation [P0995]. This activates CXCL1 transcription, leading to the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and subsequent tumor immune evasion [P0995]. By targeting tRF-21, antago-tRF-21 reduces PMN-MDSC accumulation, suppresses tumor growth, and enhances the efficacy of immunotherapy, such as anti-PD-1 therapy [P0995].
- Other names
- antagotRF-21antagotRF21antagotRF 21
Beyond the preview
Go deeper on antago-tRF-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antago-tRF-21.